It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.


ZARXIO Success▾  |  Cost Savings▾  |  Manufacturing

Sandoz: A leader in patient access, savings, and manufacturing1-4

Sandoz, a global market leader, has proven that biosimilars can create expanded patient access while increasing healthcare savings1,5,6

ZARXIO® (filgrastim-sndz) was the first FDA-approved biosimilar1

ZARXIO® (filgrastim-sndz) was the first FDA-approved biosimilar1

*”Most” defined as a comparison to NEUPOGEN® (filgrastim), Granix® (tbo-filgrastim), and NIVESTYM® (filgrastim-aafi) in terms of combined medical and pharmacy benefit status. “Unrestricted” defined as on formulary, managed to Prescribing Information, and not requiring prior authorization and step edits. Coverage defined as “Exclusive or Co-Preferred” on commercial, Medicare, health exchange plans, and pharmacy benefit managers (PBMs) on pharmacy benefit, and commercial, Medicare and health exchange plans on medical benefit according to Managed Markets Insight & Technology (MMIT) data as of September 2019.12

ZARXIO cost savings may liberate healthcare resources and expand patient access

Savings were driven by biosimilar filgrastim

Net cost savings with biosimilars in the filgrastim market

ZARXIO is the #1 prescribed filgrastim and holds 48% of the prefilled syringe filgrastim market

Based on year-to-date sales as of December 2022; based on filgrastim net sales of $3.5 billion.2
Estimated refers to the extrapolation of the estimated spend based on the assumption that there are no biosimilars in the market.

ZIEXTENZO can result in payer savings and increased patient access

A new budget impact model demonstrated a 1-million-member health plan could save millions of dollars in healthcare costs by converting patients to biosimilar ZIEXTENZO16

Payer savings
Health Plan

In an economic analysis simulation model, a hypothetical panel of 20,000 cancer patients switching from Neulasta® (pegfilgrastim) to ZIEXTENZO were expected to result in payer savings and increased treatment access5

Conversion Charts

Quality and supply reliability ensured through a state-of-the-art manufacturing process4,17

quality and supply

G-CSF=granulocyte colony-stimulating factor; IDN=integrated delivery network.

NEUPOGEN is a registered trademark of Amgen Inc.
Granix is a registered trademark of Teva Pharmaceutical Industries Ltd.
NIVESTYM is a registered trademark of Pfizer Inc.

References: 1. FDA approves first biosimilar product Zarxio [press release]. Rockville, MD: US Food and Drug Administration; March 6, 2015. 2. Data on file. Filgrastim Net Sales Analysis Model. Sandoz Inc. January 2023. 3. US Food and Drug Administration. Presented at: FDA Oncologic Drugs Advisory Committee Meeting; January 7, 2015. 4. Data on file. Novartis Manufacturing Manual Version 2.0. Sandoz Inc. 5. Wang W, Campbell K, Balu S. Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (febrile) neutropenia and expanded access based on budget neutral basis. J Clin Oncol. 2019;37(suppl 15):6645. doi:10.1200/JCO.2019.37.15_suppl.6645. 6. Data on file. Periodic Safety Update Report Overview. Princeton, NJ: Sandoz Inc; May 2022. 7. Data on file. ZARXIO and ZIEXTENZO Market Share Analysis. Sandoz Inc. May 2023. 8. Data on File. Princeton NJ: Sandoz Inc; March 2023. 9. Puckrein G, Xu Liu, Ryan A, Campbell K, Balu S. Potential Medicare beneficiary out-of-pocket reductions through using biosimilar filgrastim-sndz over reference filgrastim: a simulation analysis. Poster presented at: AMCP Nexus; October 22–25, 2018; Orlando, Florida. 10. Data on file. Sandoz ZARXIO Wholesale Acquisition Cost (WAC) Data November 2020 Resource. Sandoz Inc. November 2020. 11. Trautman H, Szabo E, James E, Tang B. Patient-administered biologic and biosimilar filgrastim may offer more affordable options for patients with nonmyeloid malignancies receiving chemotherapy in the United States: a budget impact analysis from the payer perspective [published online ahead of print August 6, 2018]. J Manag Care Spec Pharm. 2018;1-9. doi:10.18553/jmcp.2018.18094. 12. Data on file. IDN Qualitative Insights Series Presentation created by Zitter Health Insights. Sandoz Inc. 2018. 13. Data on file. Zitter Sandoz Neutropenia Commercial Pharmacy and Medical Coverage Analysis. Princeton, NJ: Sandoz Inc; 2019. 14. Short Acting Filgrastim Medical Coverage. Yardley, PA: MMIT; April 2023. 15. Short Acting Filgrastim Pharmacy Coverage. Yardley, PA: MMIT; April 2023. 16. Wang W, Li E, Campbell K, Ribes D. A budget impact analysis on the prophylactic use of biosimilar pegfilgrastim-bmez in non-myeloid cancer patients at risk of chemotherapy-induced febrile neutropenia and its expanded use to intermediate-risk patients. Poster presented at: AMCP Nexus; April 21–24, 2020. 17. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405-417.